Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Other: Sham Procedure
Drug: KVD001 Injection

Registration Number: NCT03466099

Lead Sponsor: KalVista Pharmaceuticals, Ltd.

Brief Summary: This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized to receive either a high dose, a low dose or a sham control treatment. The study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 129

Inclusion Criteria

Confirmed diagnosis of Type I or Type II diabetes mellitus (DM).
BCVA of ≥19 letters (~20/400) and ≤73 letters (~20/40) in the study eye and ≥34 letters(~20/200 or better) in the fellow eye.
Presence of ciDME in the study eye defined as CST ≥305 μm in women and ≥320 μm in men
Subjects first anti-VEGF injection in the study eye occurred ≤36 months.
Subjects have received at least 3 anti-vascular endothelial growth factor (VEGF) injections in the study eye within a 6-month period.
The last anti-VEGF injection in the study eye is ≥ 8 weeks.

Exclusion Criteria

Evidence of ocular pathology (e.g. visually significant cataract) that impacts subject's vision in the study eye from any cause other than DME.
Evidence/presence of amblyopia, vitreomacular traction, epiretinal membrane, foveal atrophy, or foveal ischemia, or any other condition in the macula that is thought to impair the subject's vision (other than DME).
Prior treatment with panretinal photocoagulation or focal grid macular photocoagulation in the study eye within the previous 3 months.
Prior treatment with intravitreal (IVT) steroid in the study eye (in the previous 3 months for triamcinolone, previous 6 months for Ozurdex and at any time for Iluvien).
Prior treatment with topical NSAIDs or topical steroids in the study eye within 1 month.
Prior treatment with systemic corticosteroids or systemic anti-VEGF therapy within 3 months.
Prior vitrectomy in the study eye.
Prior intraocular surgery in the study eye except for cataract surgery. Cataract surgery within the previous 6 months in the study eye is excluded.
Intraocular pressure (IOP) of >22 mmHg in the study eye or use of >2 antiglaucoma agents (combination agents count as 2 agents) in the study eye.
Evidence of infectious dacrocystitis, significant blepharitis, active conjunctivitis, infectious keratitis, or scleritis in either eye, or any other condition that might affect the safety of the IVT injection.
Current active proliferative diabetic retinopathy (PDR), active anterior segment neovascularization (ASNV), active retinal neovascularization, or the presence of vitreous hemorrhage in the study eye.
Poorly controlled DM.
Uncontrolled hypertension
Prior treatment with ocriplasminin the study eye within 3 months

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sham Procedure	Sham Procedure	-
KVD001 Injection (high dose)	KVD001 Injection	-
KVD001 Injection (low dose)	KVD001 Injection	-

Primary Outcome Measures

Name	Time	Method
BCVA	16 weeks	Change from Baseline in Best Corrected Visual Acuity (BCVA)

Secondary Outcome Measures

Name	Time	Method
DRSS	16 weeks	Assessments of Diabetic Retinopathy Severity Score (DRSS, scale 10-85) to evaluate the percentage of eyes with a ≥2 step reduction in score from the baseline retinopathy severity as graded from fundus photography. Minimum and maximum values of the DRSS are 10 and 85, with the low end of the scale indicating absence of retinopathy which, as the score increases, so does the severity of the retinopathy such that a score of 85 is indicative of advanced proliferative diabetic retinopathy
CST	16 weeks	Assessments of Central Subfold Thickness (CST) - analysis of covariance of change from baseline in the study eye at week 16